IMGN - ImmunoGen GAAP EPS of -$0.17 beats by $0.01 revenue of $28M beats by $2.07M

ImmunoGen press release (NASDAQ:IMGN): Q4 GAAP EPS of -$0.17 beats by $0.01. Revenue of $28M (-67.4% Y/Y) beats by $2.07M. For 2022, ImmunoGen expects: revenues between $75 million and $85 million vs. $64.5M consensus. operating expenses between $285 million and $295 million; and cash and cash equivalents at December 31, 2022, to be between $245 million and $255 million. expects that its current cash, combined with anticipated product and collaboration revenues, will fund operations into 2024.

For further details see:

ImmunoGen GAAP EPS of -$0.17 beats by $0.01, revenue of $28M beats by $2.07M